Related Experiment Video
Updated: May 25, 2026

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
Published on: March 5, 2022
Associations of adiponectin gene polymorphisms with polycystic ovary syndrome: a meta-analysis
Hongxia Jia1, Lili Yu, Xuxiao Guo
1Department of Endocrinology and Metabolism, The General Hospital of Jinan Military Command, 25 Shifan Road, Jinan 250031, People's Republic of China.
Abstract:
Adiponectin gene polymorphisms have been implicated in polycystic ovary syndrome (PCOS) development. However, results from previous studies were inconsistent and inconclusive. To shed some light on the relationship of two adiponectin gene polymorphisms, T45G and G276T, with PCOS, we conducted the current meta-analysis. PubMed was used for searching all eligible studies up to September 30, 2011. Odds ratio (OR) with the corresponding 95% confidence interval (CI) was adopted to evaluate the strength of the associations. In total, ten case-control studies involving 2,821 participants were included in the meta-analysis. Results showed that the T45G polymorphism was not associated with PCOS for allelic contrast (OR = 1.10, 95%CI: 0.83-1.44, P = 0.514), with evidence of large heterogeneity (P(heterogeneity) = 0.002). Concerning G276T polymorphism, the results showed that the T allele was related to a reduced risk of PCOS compared with the G allele under allelic genetic model (OR = 0.81, 95%CI: 0.70-0.93, P = 0.003), and no significant heterogeneity (P(heterogeneity) = 0.268) was revealed. Similar results were observed under additive, dominant and recessive genetic models for both of these two polymorphisms. No publication bias was detected. Our results suggested that the T45G polymorphism of adiponectin gene was not significantly associated with PCOS, while the G276T polymorphism was related to a decreased risk of PCOS.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Oogenesis
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

